Sertindole (Serdolect): Preclinical and clinical findings of a new atypical antipsychotic

This review first describes the preclinical findings with sertindole, a novel phenyl indole derivative antipsychotic agent. Secondly, a summary is provided of the major clinical trials conducted to date. Based on these findings, sertindole appears to be an effective antipsychotic agent for the treatment of positive and negative symptoms of schizophrenia, with efficacy that is clearly superior to placebo. Sertindole is as effective as haloperidol, but is much better tolerated with significantly fewer adverse neurological effects across a wide dosage range of both drugs. Sertindole is associated with a significant mean prolongation of the QT and QT(c) intervals of 3 - 6% from baseline in placebo-controlled studies. This potential adverse effect should be taken into account when treating specific patients with known risk factors for ventricular arrhythmias. Sertindole should prove to be a very useful addition to the therapeutic options available for the treatment of psychotic disorders.